QBiotics Group Limited
QBiotics is an Australian life sciences company specializing in the discovery and development of novel cell signaling small molecules for complex medical conditions, with a focus on oncology and wound healing. They apply phenotypic screening and have strategic research partnerships worldwide. Their mission is to improve lives globally through innovative pharmaceuticals derived from nature.
Industries
Nr. of Employees
small (1-50)
QBiotics Group Limited
Products
Intratumoural small‑molecule oncology candidate (human development)
A plant‑derived small‑molecule candidate administered by intratumoural injection being developed for treatment of a range of solid tumours; has progressed through first‑in‑human studies and into Phase II clinical trials.
Registered veterinary intratumoural oncology product (commercialized formulation)
A veterinary formulation of an intratumoural small‑molecule oncology therapeutic that is registered and marketed for veterinary use across multiple regions via a commercial partner.
Wound‑healing small‑molecule candidate (early clinical)
A small‑molecule candidate targeting chronic and acute wounds and burns, advanced to first‑in‑human Phase I safety trials for venous leg ulcers.
Preclinical anti‑virulence antibiotic discovery programme
Discovery‑stage programme focused on small molecules that inhibit bacterial virulence as an alternative antibiotic approach.
Intratumoural small‑molecule oncology candidate (human development)
A plant‑derived small‑molecule candidate administered by intratumoural injection being developed for treatment of a range of solid tumours; has progressed through first‑in‑human studies and into Phase II clinical trials.
Registered veterinary intratumoural oncology product (commercialized formulation)
A veterinary formulation of an intratumoural small‑molecule oncology therapeutic that is registered and marketed for veterinary use across multiple regions via a commercial partner.
Wound‑healing small‑molecule candidate (early clinical)
A small‑molecule candidate targeting chronic and acute wounds and burns, advanced to first‑in‑human Phase I safety trials for venous leg ulcers.
Preclinical anti‑virulence antibiotic discovery programme
Discovery‑stage programme focused on small molecules that inhibit bacterial virulence as an alternative antibiotic approach.
Services
Discovery partnerships using phenotypic screening and natural product scaffolds
Collaborative biodiscovery programmes applying phenotypic screening to rainforest‑derived molecular scaffolds to identify small‑molecule leads.
Clinical development and regulatory submission support
End‑to‑end preparation of preclinical and CMC documentation, IND submissions, and management of early‑phase clinical trials (Phase I–II) including translational research objectives.
Partnerships for veterinary commercialization and market access
Partner‑led commercialization of veterinary pharmaceutical formulations with regional market approvals and launch support.
Discovery partnerships using phenotypic screening and natural product scaffolds
Collaborative biodiscovery programmes applying phenotypic screening to rainforest‑derived molecular scaffolds to identify small‑molecule leads.
Clinical development and regulatory submission support
End‑to‑end preparation of preclinical and CMC documentation, IND submissions, and management of early‑phase clinical trials (Phase I–II) including translational research objectives.
Partnerships for veterinary commercialization and market access
Partner‑led commercialization of veterinary pharmaceutical formulations with regional market approvals and launch support.
Expertise Areas
- Clinical trial management (Phase I–II)
- Biodiscovery of natural product small molecules
- Translational research and tumour microenvironment analysis
- Veterinary‑to‑human translational development
Key Technologies
- Phenotypic drug screening
- Rainforest‑derived natural product biodiscovery
- Small‑molecule drug discovery
- Intratumoural drug delivery